AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Markus Renschler, M.D.
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
140 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal North Shore Hospital
St Leonards, New South Wales, Australia
- New South Wales Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
- the Princess Alexandra Hospital, Dept of Respiratory Medicine
Woolloongabba, Queensland, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- the Queen Elizabeth Hospital
Woodville South, Australia
- Allgemeines Krankenhaus Der Stadt Linz, Abteilung Fur Atem Und Lungenkrankheiten
Linz, Austria
- Allegemeines Krankenhaus Wien, Univ. Klinik Fur Innere, Medizin I
Vienna, Austria
- Krankenhaus Hietzing, 5 Med. Abteilung Mit Onkologie
Vienna, Austria
- Klinikum Weis-Grieskirchen Gmbh
Wels, Austria
- Uz Brussel, Medical Oncology and Hematology
Brussels, Belgium
- Centre Hospitalier Notre-Dame Et Reine Fabiola
Charleroi, Belgium
- Universitair Ziekenhuis Antwerpen, Dept. Respiratory Diseases
Edegem, Belgium
- Uz Gasthuisberg, Uz Leuven
Leuven, Belgium
- C.H.U. Sart-Tilman
Liège, Belgium
- Iii-Rd Internal Department, District Dispensary for Oncology Diseases With Stationary(ddoncdiu)
Plovdiv, Bulgaria
- Ddoncdiu Sofia District
Sofia, Bulgaria
- Mhat "tsaritsa Yoanna"
Sofia, Bulgaria
- University Multiprofile Hospital for Active Treatment "sveta Marina"
Varna, Bulgaria
- Fraser Valley Cancer Centre-Surrey Memorial Hospital
Surrey, British Columbia, Canada
- London Regional Cancer Centre
London, Ontario, Canada
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Humber River Regional Hospital
Weston, Ontario, Canada
- Royal Victoria Hospital
Montreal, Quebec, Canada
- Fakultni Nemocnice Ostrava
Ostrava-Poruba, Czechia
- Faculty Hospital Motol
Prague, Czechia
- Fakultní Thomayerova Nemocnice S Poliklinikou
Prague, Czechia
- Masarykova Nemocnice V Ústí Nad Labem
Ústí nad Labem, Czechia
- Rikshospitalet, Finsen Center
Copenhagen, Denmark
- Herlev Hospital, Onkologisk Afdeling R
Herlev, Denmark
- Odense Universitetshospital,onkologisk Afdeling R
Odense C, Denmark
- Centre François Baclesse
Caen, France
- Hôpital de la Croix-Rousse
Lyon, France
- Chu Montpellier - Unité de Cancérologie Thoracique
Montpellier, France
- Institut Gustave Roussy
Villejuif, France
- Zentralklinik Bad Berka Gmbh
Bad Berka, Germany
- Charité Universitätsmedizin Berlin
Berlin, Germany
- Universitätsklinikum Essen Innere Klinik Und Poliklinik
Essen, Germany
- Asklepios Fachkliniken Muenchen Gauting
Gauting, Germany
- Krankenhaus Grosshansdorf, Zentrum Fur Pneumologie Und Thoraxchirurgie
Großhansdorf, Germany
- Staedtisches Krankenhaus Martha-Maria Halle-Doelau
Halle, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Sept 2007
- Primary completion
- 1 May 2011
- Completion
- 1 May 2011
- Last update posted
- 6 Nov 2019
- Registered enrollment
- 637
- Registry id
- NCT00547651
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.